Abdulrahman S Alanazi
Overview
Explore the profile of Abdulrahman S Alanazi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alenezi E, AlQahtani A, Althunayan S, Alanazi A, Aldosari A, Alharbi A, et al.
Cureus
. 2024 Jan;
15(12):e51205.
PMID: 38283470
Globally, the frequency of road traffic accidents (RTAs) is sharply rising. It is concerning that the number of RTAs in the Kingdom of Saudi Arabia (KSA) has risen within the...
2.
Alanazi W, Alanazi A, El-Nagar D, Aljuraybah A, Alsanea S, Alharbi M
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259438
Tivozanib is a triple vascular endothelial growth factor receptor inhibitor, recently approved for the treatment of refractory advanced renal cell carcinoma. Clinical studies showed that around 46% of patients who...
3.
Alanazi W, Alhamami H, Alharbi M, Alhazzani K, Alanazi A, Alsanea S, et al.
Saudi Pharm J
. 2022 Sep;
30(8):1159-1169.
PMID: 36164571
Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), used for the treatment of advanced or metastatic non-small cell lung cancer. Recently, studies proved that...
4.
Eid E, Alanazi A, Koosha S, Alrasheedy A, Azam F, Taban I, et al.
Molecules
. 2019 Jul;
24(14).
PMID: 31337024
Cell-penetrating peptides (CPPs) are highly promising tools to deliver therapeutic molecules into tumours. αVβ3 integrins are cell-matrix adhesion receptors, and are considered as an attractive target for anticancer therapies owing...
5.
Alanazi A, Alfadl A, Hussain A
Saudi J Med Med Sci
. 2019 Feb;
4(1):9-14.
PMID: 30787688
Pharmaceutical care can be given in all settings: The community, hospitals, long-term care, and the clinic. However, published literature indicates that there is a substantial barrier to implementing pharmaceutical care...
6.
Alanazi A
Saudi Pharm J
. 2015 Dec;
23(6):603-13.
PMID: 26702254
Combinational therapies are often required in the management of type 2 diabetes mellitus (T2DM). Among the important candidates, dipeptidyl peptidase-4 inhibitors (DPPIs) and metformin combination (DPPI-MET) have shown promising endeavors....
7.
Alanazi A
Saudi Pharm J
. 2013 Oct;
21(3):233-43.
PMID: 24151428
Autism and related disorders are increasingly prevalent behavioral syndromes of impaired verbal and nonverbal communication and socialization owing to neurodevelopmental abnormalities. The most recent estimate for the prevalence of autistic...